Drugs / EPZICOM
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | EPZICOM | — | 2004-08-02 | fda.gov ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02893488 | Sep → Nov 2016 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT00708162 Background | Jul 2008 → Dec 2010 | HIV infectious disease | Gilead Sciences | Completed | Met primary |
| Phase 3 | NCT00280969 Background | Sep 2005 → Sep 2009 | HIV infectious disease | International Medical Center of Japan | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EPZICOM | “Patients are treated with ritonavir 100mg boosted atazanavir 300mg along with Epzicom.” NCT00280969 ↗ |
| Known as | ABC/3TC | “Drug: EPZICOM (ABC/3TC)” NCT02893488 ↗ |
| Route | Oral | “an oral dose of TIVICAY™ (DTG) + EPZICOM™ (ABC/3TC) non-dispersible tablets administered in the fasted state” NCT02893488 ↗ |